Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002809 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00002809 is a Phase 2 study that has completed, run by Temple University. The registered enrollment target is 10 participants.
The verdict
NCT00002809, a Phase 2 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy together with bone marrow transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bone marrow transplant from an unrelated donor together with cyclophosphamide and total-body irradiation works in treating patients with hematologic cancer.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL sargramostim
- BIOLOGICAL therapeutic immune globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1996-08 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002809
The ClinicalTrials.gov registry entry for NCT00002809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002809 about?
NCT00002809 is a clinical study titled "Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy together with bone marrow transplant may allow the doctor to give hi...
What is the current status of trial NCT00002809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 1996-08. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00002809?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), anti-thymocyte globulin (BIOLOGICAL), sargramostim (BIOLOGICAL), therapeutic immune globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002809?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.